JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
:2126
Top Page
JW (Cayman) Therapeutics Co. Ltd.
(2126)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$2.50
▲(0.00% Upside)
Action:ReiteratedDate:11/19/25
The overall stock score is primarily impacted by the company's financial performance, which shows strong revenue growth but significant profitability challenges. Technical analysis indicates bearish momentum, while valuation metrics are unfavorable due to negative earnings and lack of dividends.
Positive Factors
Sustained Revenue Growth
Reported multi-year revenue growth indicates expanding commercial traction and/or progress in clinical asset value. Durable revenue growth supports continued R&D investment, strengthens negotiating position for partnerships, and underpins long-term development funding needs amid rising cell-therapy demand.
Negative Factors
Persistent Unprofitability
Ongoing negative net income and EBIT margins limit internal capital generation and weaken returns to shareholders. Persistent losses constrain the company's ability to self-fund expansion and increase dependency on external financing, raising execution and dilution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Reported multi-year revenue growth indicates expanding commercial traction and/or progress in clinical asset value. Durable revenue growth supports continued R&D investment, strengthens negotiating position for partnerships, and underpins long-term development funding needs amid rising cell-therapy demand.
Read all positive factors
JW (Cayman) Therapeutics Co. Ltd. (2126) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$912.08M
Dividend YieldN/A
Average Volume (3M)2.67M
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue Growth2.45%
EPS Growth2.58%
CountryHK
Employees281
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.76
Shares Outstanding416,473,240
10 Day Avg. Volume1,852,649
30 Day Avg. Volume2,667,300
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.43
Price to Sales (P/S)3.14
P/FCF Ratio-1.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.77
Revenue Forecast (FY)HK$312.38M
JW (Cayman) Therapeutics Co. Ltd. Business Overview & Revenue Model
Company Description
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies...
How the Company Makes Money
JW (Cayman) Therapeutics generates revenue through several key streams. Primarily, the company earns money from the commercialization of its proprietary cell therapy products once they receive regulatory approval and are launched in the market. Ad...
JW (Cayman) Therapeutics Co. Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 177.75M | 158.22M | 173.86M | 145.70M | 30.80M | 0.00 |
| Gross Profit | 98.69M | 77.32M | 88.22M | 58.76M | 9.04M | 0.00 |
| EBITDA | -256.23M | -381.58M | -655.75M | -752.27M | -738.70M | -454.04M |
| Net Income | -617.62M | -590.62M | -768.00M | -846.13M | -702.33M | -1.66B |
Balance Sheet | ||||||
| Total Assets | 1.42B | 1.68B | 2.15B | 2.79B | 3.12B | 3.78B |
| Cash, Cash Equivalents and Short-Term Investments | 647.04M | 762.53M | 1.01B | 1.39B | 1.84B | 2.63B |
| Total Debt | 372.46M | 422.40M | 318.80M | 279.13M | 147.03M | 123.59M |
| Total Liabilities | 510.83M | 511.20M | 462.26M | 437.06M | 325.75M | 349.76M |
| Stockholders Equity | 908.61M | 1.17B | 1.68B | 2.35B | 2.79B | 3.43B |
Cash Flow | ||||||
| Free Cash Flow | -202.73M | -348.87M | -413.00M | -613.60M | -634.28M | -385.24M |
| Operating Cash Flow | -200.13M | -333.44M | -398.42M | -536.72M | -561.20M | -261.00M |
| Investing Cash Flow | -2.84M | -15.43M | 9.90M | -124.08M | -137.13M | -91.91M |
| Financing Cash Flow | -20.67M | 90.49M | 275.00K | 112.35M | -30.62M | 2.86B |
JW (Cayman) Therapeutics Co. Ltd. Technical Analysis
Neutral
2.50
Price Trends
2.17
Positive
2.59
Negative
3.40
Negative
Market Momentum
-0.04
Negative
58.79
Neutral
65.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2126, the sentiment is Neutral. The current price of 2.5 is above the 20-day moving average (MA) of 1.94, above the 50-day MA of 2.17, and below the 200-day MA of 3.40, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 58.79 is Neutral, neither overbought nor oversold. The STOCH value of 65.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2126.
JW (Cayman) Therapeutics Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | HK$8.81B | -76.25 | -6.26% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$1.96B | -3.21 | -184.99% | ― | ― | -18.99% | |
42 Neutral | HK$13.59B | -15.44 | -64.19% | ― | -55.64% | -158.67% | |
41 Neutral | HK$912.08M | -1.73 | -59.45% | ― | 2.45% | 2.58% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.19
0.89
68.46%
HK:9966
Alphamab Oncology
9.04
3.11
52.45%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.89
88.65%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.10
-2.90
-41.43%
HK:2616
CStone Pharmaceuticals
9.35
7.15
325.00%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.98
-1.10
-13.61%
JW (Cayman) Therapeutics Co. Ltd. Corporate Events
JW Therapeutics Grants New Share Options and RSUs to CEO and Key Staff
Jan 16, 2026
JW (Cayman) Therapeutics has granted a total of 2.6 million share options and 650,000 restricted share units to four grantees under its post-IPO equity incentive and restricted share unit schemes adopted in 2020, as part of its ongoing remuneratio...
JW Therapeutics Outlines Board and Committee Structure
Dec 29, 2025
JW (Cayman) Therapeutics Co. Ltd has announced the current composition of its board of directors, which includes one executive director, four non-executive directors and three independent non-executive directors, with Cheng Liu serving as chairman...
JW Therapeutics Extends Vector Supply Agreement With Juno to 2028
Dec 22, 2025
JW (Cayman) Therapeutics has extended the term of its vector supply agreement with substantial shareholder Juno through 31 December 2028, ensuring continued access to critical vectors used in the commercialization and further clinical development ...
JW Therapeutics Announces Key Leadership Changes
Dec 11, 2025
JW (Cayman) Therapeutics Co. Ltd. has announced significant leadership changes, including the appointment of Mr. Tian Feng as the new Chief Executive Officer and Executive Director, effective December 29, 2025. Mr. Tian brings over 20 years of exp...
JW Therapeutics Announces Board Composition and Roles
Dec 11, 2025
JW (Cayman) Therapeutics Co. Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board comprises non-executive and independent non-executive directors, with specific members servin...
JW Therapeutics Reports Promising Results for JWCAR201 in Hematology Study
Dec 8, 2025
JW Therapeutics presented promising data from its JWCAR201 study at the American Society of Hematology Annual Meeting. The study, which involved patients with relapsed/refractory diffuse large B-cell lymphoma, showed a 100% overall response rate a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.